论文部分内容阅读
米妥蒽醌(Mrr) Ⅰ、Ⅱ期试验中有重要作用。在1组随机初发AML 治疗中,用Ara-C 100mg/m~2/d×7,持续静滴;MIT 12mg/m~2/d×3,静注,或DNR45mg/m~2/d×3。未缓解者,以原方案再诱导1次,但MIT 和DNR 用2天,Ara-C 用5天。MIT 组CR 为63%,DNR 组53%。MIT 组获CR 者经1次诱导达CR 为89%,而DNR 组为68%。两组的CR 持续、生存时间和毒副作用无显著差异。4-去甲氧柔红霉素(IDA) 正在Ⅲ期试验中:Ara-C 100ms/m~2/d×7,持续静滴;IDA13mg/m~2/d×3,静注,或DNR45mg/m~2/d×3。无缓解,重复1次。缓解后用2个巩固疗程。每疗程IDA 或DNR 用2天,Ara-C 用5天,剂量同前。小于50岁组CR 率:
There are important roles in the Mrr phase I and II trials. In a randomized first-time AML treatment, Ara-C 100 mg/m~2/d*7, continuous intravenous infusion; MIT 12 mg/m~2/d*3, intravenous, or DNR 45 mg/m~2/d ×3. Those who did not respond were re-induced once in the original protocol, but MIT and DNR were used for 2 days and Ara-C was used for 5 days. The MIT group had a CR of 63% and a DNR group of 53%. In the MIT group, CR was 89% after one induction and CR was 68% in the DNR group. There was no significant difference in CR duration, survival time, and side effects between the two groups. 4-Dimethoxydaunorubicin (IDA) In phase III trial: Ara-C 100ms/m~2/d*7, continuous infusion; IDA 13mg/m~2/d*3, intravenous, or DNR45mg /m~2/d×3. No remission, repeat 1 time. After remission, use 2 consolidation sessions. Two days for each course of IDA or DNR, and five days for Ara-C, with the same dose. CR rate less than 50 years old group: